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Summary.-The cytocidal properties of metronidazole against hypoxic mammalian
cells are described. This chemotherapeutic action has been shown to be dependent
on drug concentration and duration of exposure. The x-ray TCD50 for a murine
anaplastic carcinoma was reduced from 6081 rad to 4643 rad when animals were
given metronidazole orally for 36 h before radiation treatment. The effect is attri-
buted to the direct killing of hypoxic tumour cells by a mechanism analogous to
that proposed for the action of the drug on anaerobic micro-organisms. It is
concluded that further work with metronidazole as a cytotoxin specific for hypoxic
cells is warranted, particularly in view of the reported lack of toxicity associated
with the preliminary clinical use of the drug as a radiosensitizer in man.
METRONIDAZOLE (Flagyl, May and
Baker Ltd) has been shown to be an
effective radiosensitizer of several murine
tumour systems in vivo (Begg, Sheldon
and Foster, 1974; Stone and Withers,
1974; Rauth and Kaufman, 1975). Pre-
liminary clinical trials using drug doses
of about 200 mg/kg are now being under-
taken (Urtasun et al., 1974, 1975; Deutsch
et al., 1975).
The drug was originally screened as
a radiosensitizer of hypoxic cells because
it is an organic nitro-compound possessing
extremely favourable pharmacological and
toxicological properties, which had been
emphasized several years earlier as impor-
tant prerequisites for sensitizing activity
in vivo (Emmerson and Howard-Flanders,
1965). In addition the drug is well
known for its potent cytocidal action
on anaerobic but not aerobic micro-
organisms (McFadzean, 1971).
Subsequent experiments have indi-
cated that the drug does have an ana-
logous chemotherapeutic effect on hypoxic
tumour cells. The rates of growth of
tumours of mice given metronidazole
following radiation treatment have been
found to be lower, and the rates of cell
loss higher, than those of animals given
radiation alone (Begg et al., 1974; Inch
and McCredie, 1975). The drug had also
been found to kill non-cycling, mammalian
cells grown in vitro as spheroids (Suther-
land, 1974). It was thus apparent that
prolonged continuous treatment with me-
tronidazole before and during the first
part of fractionated radiotherapy might
provide an additional method ofattacking
the problem of radioresistant hypoxic
tumour cells (Foster and Willson, 1976).
We now report experiments on mouse
tumours in which this possibility of
using metronidazole as a chemotherapeutic
agent has been further evaluated.
MATERIALS AND METHODS
(a) In vitro incubation of Ehrlich ascites
carcinoma cells.-Sterile procedures were used
throughout. Approximately 3 x 106 as-
cites tumour cells were injected into the
peritoneal cavity of CBA/CA mice. The
cells were harvested 7 days later and placed
in a tube containing 5 ml of phosphate-
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buffered saline (PBS, pH 7-3, containing
100 u of heparin). The cells were washed
with lysing buffer (7.4 g NH4C1, 2-06 g Tris
HC1 in 11 brought to pH 7 2 with conc.
HCI) to remove erythrocytes and centrifuged
at 700 g for 5 min to produce a pellet. The
pellet was gently resuspended in 5 ml PBS
and the tumour cell concentration determined
using a Coulter particle counter (model D).
Residual erythrocytes present in samples
removed for counting were lysed with
" Zapoglobin " (Coulter Electronics Ltd).
After further centrifugation the cells were
resuspended in tissue culture medium (TC199,
Wellcome Reagents Ltd, containing 200 u
of benzyl penicillin and 100 ,ug streptomycin
per ml), to a concentration of 4 x 107/ml.
This suspension was buffered to pH 7-4 using
HEPES (Flow Labs. Ltd). Aliquots (5 ml)
of this suspension were placed into amber
bottles with aluminium foil caps and gently
shaken in a water bath at 37°C for 20 min.
A further 5 ml of tissue culture medium
was added to 7 ofthese bottles and designated
controls. To the remainder, 5 ml of tissue
culture medium containing metronidazole
was added to give drug concentrations of
5mM and 10mM (10 mM = 1710 ,ztg/
ml). All the bottles were stoppered with
plastic caps through which two syringe
needles were inserted to allow equilibration
of the cell suspensions with the appropriate
gas. Pure N2 or air was gently bubbled
through the suspensions for 30 min. The
needles were then removed and the caps of
the bottles containing cells equilibrated with
N2 were sealed. The caps of those bottles
containing cells that had been equilibrated
with air were replaced with loose-fitting
aluminium foil. All the bottles containing
the cells were then incubated for 0, 2, 4 or
6 h at 37°C whilst being gently shaken to
ensure that the cells remained in suspension,
and that they continued to be in equilibrium
with the appropriate gas. After the required
intervals 0-2 ml aliquots ofthe cell suspension
(4 x 106 cells) were injected into groups of
5 or 10 CBA/CA mice from the inbred
Brunel colony. The times of death of the
mice were recorded.
(b) Tumour control probability determina-
tion.-Syngeneic female CBA/Ht mice were
used in batches of 100. A fast-growing
anaplastic carcinoma, designated NT, was
transplanted subcutaneously by trocar on
to the ventral surface of the thorax whilst
the animals were under Penthrane-induced
anaesthesia.
The resulting tumours were measured
twice a week with Vernier calipers and
those mice with tumours of approximately
5 mm diameter were selected for use. Each
selected batch was divided into two: one
half was set aside and 2 days later these
mice were assigned to one of 6 radiation
dose groups. The other half was given an
oral dose of metronidazole (0.3 mg/g body
wt.) every 6 h for 36 h (6 administra-
tions) and irradiated 6-8 h after the last
drug dose. All the mice were irradiated as
described previously (Begg et al., 1974)
with 240 kV x-rays (HVL 1-3 mm Cu) at
a dose rate of 240 rad/min whilst breathing
air at room temperature. The mice were
then kept for 130 days. Those mice de-
veloping tumours greater than 8 mm in
diameter were scored as recurrences. The
x-ray dose required to cure 50% of the
mice (TCD50) and the s.e. mean of this
value was calculated from the percentage
cures using a computer program (Peters
and Porter, private communication). The
program assumes that single cell survival
kinetics apply so that the probability of
tumour control is given by exp (-SN)
where N is the initial number of clonogenic
cells and S is the recurring (i.e. surviving)
fraction which is an exponentially decreasing
function of dose.
Another batch of tumour-bearing mice
was dosed with metronidazole as described
above. At hourly intervals, for up to 8 h,
groups of 3 or 4 mice were exsanguinated
by heart puncture whilst under ether-induced
anaesthesia. The concentration of metro-
nidazole in the serum from these blood
specimens was measured by polarography
(Kane, 1961).
RESULTS
(a) In vitro incubation of Ehrlich ascites
tumour cells
The results are shown in the table.
Incubation of the cells in metronidazole
under aerated conditions resulted in little
or no increase in survival time of mice
injected with these cells compared with
those injected with control cell samples.
In contrast a large increase in survival
time was seen in mice receiving cells
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TABLE.-Survival Time of Male CBA/CA Mice Receiving a Standard Inoculum of
Ehrlich Ascites Carcinoma Cells After Treatment with Metronidazole Under Anoxic
and Aerated Conditions
Anoxic
Mean day of death Range of
Is.e. mean death
18-7±0-45 17-21
20-6±0-92 18-23
18-810-47 17-21
21 -4±0-60
21 0±1-05
22 4±0 67
22-0±0-60
25-8±1 -64
>46.8*±6.34
21 6±1 09
>60
>60
Aerated
Mean day of death Range of
±s.e. mean death
18-2±0-49 17-19
17-4±0-40 17-19
20-23
17-23
21-24
19-24
-24-27
22->60
13>24
>60
>. 60
19-2±0-49 18-20
22-2± 1-07 20-26
21-8±0-80 19-23
25-4±2-18 22-34
* Mean survival time of 5 animals; the remaining 5 animals within this group lived beyond day 60 and
were arbitrarily defined as indefinite survivors.
t Cells removed immediately after gassing.
treated with metronidazole under anoxic
conditions. Six hours' exposure to 5mM
metronidazole was required to cause
a significant increase in survival time
A marked effect was seen after only.
4 h exposure to 10 mM metronidazole.
(b) Tumour control probability determina-
tion
The results of the tumour irradiation
experiment are shown in Fig. 1. Tumours
in the metronidazole-treated mice show
an increased sensitivity to irradiation.
A dose of 4643 rad +97 controlled 50%
of the tumours in the drug-treated mice
compared with a dose of 6081 + 135
for the control group. It can be seen
(Fig. 1) that for a dose of 5300 rad less
than 20% of the control mice were
cured compared with over 80% of the
drug-treated mice.
The serum concentration/time curve
(Fig. 2) indicates that the serum con-
centration of metronidazole at the time
of irradiation was less than 30 ,tg/ml.
The peak concentration of the drug was
in the region of 200 ,tg/ml and the half-
life of metronidazole in the serum was
approximately 1N h. No mice were lost
from this study due to drug toxicity.
However, 8/64 animals from the drug-
treated group were excluded from the
experiment due to the development of
metastases, mainly in the lungs, and
similarly 15/101 from the control group.
Also, 9 mice died within 3 weeks of
irradiation due to the unavoidable occa-
sional inclusion of part of the intestine
in the radiation field in a few cases.
DISCUSSION AND CONCLUSION
The results of the incubation of
ascites cells with metronidazole in vitro
clearly shows that the drug is cytocidal
for anoxic cells at concentrations pro-
ducing little or no effect on aerated cells.
It has been reported (Hawes, Howard
and Gray, 1964) that incubation of
ascites cells under anaerobic conditions
with or without mechanical agitation
greatly reduces the viability of these
cells and increases their radiosensitivity.
In the present study no reduction was
seen in the survival time of mice injected
with cells incubated under anoxic condi-
tions for up to 6 h when compared with
the analogous aerated controls. How-
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FIG. 1.-The percentage of tumours as a function of x-ray dose for transplanted anaplastic carcino-
mata in CBA/Ht mice. x tumours given x-rays only. 0 tumours given x-rays after the mice
received 36 h metronidazole treatment. Curves drawn by eye. Horizontal bars ± s.e. mean.
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FIG. 2. The serum concentration of metro-
nidazole as a function oftime after the last of
6 injections of 0 3 mg/g body wt. spaced
6 h apart.
ever, it is possible that the ascites cells
which were incubated under N2 were
made unusually sensitive to the cytotoxic
effect of metronidazole. If this is to
invalidate our conclusion, then a dif-
ference between cells that are naturally
hypoxic in vivo (i.e. hypoxic tumour
cells) and the cells as we have used
them in vitro would have to be demon-
strated.
It is not possible to make a quantita-
tive estimate of the fraction of cells
killed by the drug treatment schedules
used in this experiment. However, there
can be little doubt that the increased
survival time of the mice receiving the
drug-treated cells is due to a substantial
reduction of the viable fraction of the
standard cell inoculum. Since these stu-
dies were begun a similar effect of metro-
nidazole against anoxic mammalian cells
has been reported (Mohindra and Rauth,
1976). Nitrofurazone was found to
be similarly active. In vitro experiments
also showed that the activity is de-
pendent on cell type, 02 concentration,
temperature of incubation and concen-
tration of both drugs. Recently a 2-
nitroimidazole drug has also been found
to be cytocidal for anoxic mammalian
cells (Hall and Roizin-Towle, 1975). Ex-
posure of anoxic cells to this drug for up
to 24 h resulted in marked cell killing
with drug concentrations as low as 200
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,tg/ml. Results from studies with frac-
tionated irradiations led to the suggestion
that exposure to the drug between doses
of radiation prevents the repair of sub-
lethal radiation damage.
The increased sensitivity of the solid
carcinoma to x-rays reported here is
interpreted as beiig due to the killing
of a substantial fraction of the hypoxic
cells in the tumour by the metronidazole
treatment before irradiation. For signi-
ficant radiosensitization of hypoxic cells
to occur in vitro (Asquith et al., 1974)
or in vivo (Rauth and Kaufman, 1975)
it has been found that metronidazole
concentrations 5 times greater than the
value of 30 ,ag/ml found in the present
studyarerequired atthetime ofirradiation.
Unfortunately, the fast growth rate
of murine tumours of the type used in
this experiment restricts the time avail-
able for pre-irradiation treatment with
a drug. In particular, the short half-life
of metronidazole in mice (11 h) means
that either the drug has to be administered
very frequently or very high drug doses
have to be used to maintain an effective
drug concentration over an extended
time period. The design of the experi-
ments reported here took these factors
into account as far as possible. It is
not known how fast hypoxic cells are
generated in the tumour used nor the
minimum effective concentration ofmetro-
nidazole under in vivo conditions. There-
fore, it is possible that some hypoxic
tumour cells survived the treatment
schedule used. For these reasons further
experiments have been started where
metronidazole has been administered for
a time after irradiation as well as before
and in which a range of drug doses has
been used. The serum half-life of metro-
nidazole in man is 8-10 h and the growth
rate of most solid human neoplasms is
much slower than their murine counter-
parts. Thus any future clinical applica-
tion will be more straightforward than
might be suggested by the present experi-
ments. The drug regimes reported are
directly applicable only to mice.
It is probable that many organic
nitro-aromatic compounds have activity
against anoxic mammalian cells. On re-
duction, whether by radiation or bio-
chemically, they can form a toxic species
(Willson, Cramp and Ings, 1974; Willson
and Searle, 1975; Foster and Willson
1976). In the case of metronidazole this
species is either inactivated by 02 or
only produced in its absence; hence the
drug's lack of activity on aerobic micro-
organisms (Ings, McFadzean and Ormerod,
1974), or on normal well-oxygenated
cells as reported herein. Thus, as with
radiosensitizers, drugs which show the
greatest efficiency on hypoxic cells in
vitro (i.e. having relatively high one-
electron electrode potentials), are more
likely to produce unacceptable side-effects
in vivo.
In conclusion we suggest that the use
of metronidazole as a cytotoxin specific
for hypoxic cells in solid tumours should
be more fully explored. The lack of
unwanted side-effects recently reported
following its use as a radiosensitizer, in
man at high doses, is encouraging (Urtasun
et al., 1975). In addition, the use of the
drug as a chemotherapeutic agent before
the commencement ofradiotherapy would
obviate the necessity of altering well
established fractionation schedules to
accommodate tolerable drug regimes.
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